| 1 |
31350763 | Sorafenib Activity and Disposition in Liver Cancer Does Not Depend on Organic Cation Transporter 1. | 2020 Jan |
3 |
| 2 |
31953214 | Relationship between changes in the exon-recognition machinery and SLC22A1 alternative splicing in hepatocellular carcinoma. | 2020 May 1 |
3 |
| 3 |
30592786 | Epigenetic events involved in organic cation transporter 1-dependent impaired response of hepatocellular carcinoma to sorafenib. | 2019 Mar |
4 |
| 4 |
30972782 | Causes of hOCT1-Dependent Cholangiocarcinoma Resistance to Sorafenib and Sensitization by Tumor-Selective Gene Therapy. | 2019 Oct |
4 |
| 5 |
31413596 | Role of OCT1 in hepatocellular carcinoma. | 2019 |
1 |
| 6 |
29983874 | Role of drug transporters in the sensitivity of acute myeloid leukemia to sorafenib. | 2018 Jun 19 |
3 |
| 7 |
28178663 | The lack of the organic cation transporter OCT1 at the plasma membrane of tumor cells precludes a positive response to sorafenib in patients with hepatocellular carcinoma. | 2017 Feb 28 |
3 |
| 8 |
26872727 | Organic Cation Transporter 1 (OCT1) mRNA expression in hepatocellular carcinoma as a biomarker for sorafenib treatment. | 2016 Feb 12 |
7 |
| 9 |
23482500 | Sorafenib hepatobiliary disposition: mechanisms of hepatic uptake and disposition of generated metabolites. | 2013 Jun |
2 |
| 10 |
23532667 | Expression of SLC22A1 variants may affect the response of hepatocellular carcinoma and cholangiocarcinoma to sorafenib. | 2013 Sep |
12 |
| 11 |
23984399 | Role of the plasma membrane transporter of organic cations OCT1 and its genetic variants in modern liver pharmacology. | 2013 |
3 |